Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.

Abstract

A 64-year-old man with history of prostate adenocarcinoma underwent radical prostatectomy in 2003. He remained with undetectable prostate-specific antigen (PSA) levels until 2014, when he then presented rising serum PSA levels and performed a Tc-MDP bone scan that was negative for metastases. In August 2015, his PSA was 4.89 ng/dL, and restaging images with pelvic MR and F-FDG PET/CT were both negative. Therefore, the patient underwent a Ga-PSMA PET/CT that showed marked tracer uptake in a single mediastinal lymph node. Histopathology demonstrated metastatic adenocarcinoma secondary to prostate cancer, altering patient management to hormone therapy instead of pelvic radiotherapy.

DOI: 10.1097/RLU.0000000000001264

Cite this paper

@article{Queiroz2016ClinicalIO, title={Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.}, author={Marcelo Ara{\'u}jo Queiroz and P{\'u}blio C{\'e}sar Cavalcante Viana and Allan de Oliveira Santos and Diogo Assed Bastos and Elba Cristina de S{\'a} Camargo Etchebehere and Giovanni Cerri}, journal={Clinical nuclear medicine}, year={2016}, volume={41 9}, pages={e417-9} }